673 total views, 12 views today
Bio-pharmaceutical company to join with Maryland-based organizations at Asia’s premier biotechnology partnering event
Rockville, MD – October 5, 2022 – Tasly Pharmaceuticals, Inc. (Tasly U.S.), “dedicated to a healthier world,” will join a delegation of other Maryland-based bio-pharmaceutical companies at BioJapan 2022, Asia’s premier partnering event for the global biotechnology sector, in Yokohama, Japan, October 12 to 14.
Tasly U.S., whose vision is “to change the way the world takes and understands medicine,” will discuss its development of T89 (Dantonic), which has become the first herbal medicine-derived compound to complete a U.S. Food and Drug Administration Phase III global clinical trial, with promising data.
“Tasly U.S. is positioned to become a world-renowned innovator in pharmaceuticals, biologics, and nutraceuticals, and we see BioJapan 2022 as an opportunity to introduce the biotechnology world to our capabilities, our products in development, and our unique perspective,” said Dr. He Sun, President and CEO of Tasly Pharmaceuticals, Inc.
In addition to presenting and discussing its products, used in the treatment of cardiovascular disease, non-alcoholic fatty liver disease (NAFLD) and Tourette Syndrome, etc., Dr. Sun said Tasly U.S. will be open to discuss business collaboration and drug co-development with other BioJapan 2022 exhibitors and participants.
BioJapan 2022 will take place at PACIFICO Yokohama Hall B/C/D Annex Hall North on October 12, 13 and 14, from 10:00 a.m. to 5:00 p.m. each day.
About Tasly U.S.
Tasly Pharmaceuticals, Inc. (Tasly U.S.) is “dedicated to a healthier world.” We provide effective, safe, and high-quality herbal-based alternative medicines for the benefit of the medical/healthcare community and its patients, and to provide solutions to reduce side effects caused by medications.
Founded in 2006, and following years of research and development, Tasly U.S., based in Rockville, Maryland, is positioned to become a world-renowned innovator in pharmaceuticals, biologics, and nutraceuticals.
Among its key accomplishments to date: T89 (Dantonic) has become the first herbal medicine-derived compound to complete an FDA Phase III global trial, yielding promising data. Results indicate that T89’s pharmacological functionalities express clinically significant benefits, including improving blood circulation, boosting energy metabolism level, and reducing blood viscosity.
Tasly U.S. believes its initial success with T89 will pave the way for the broader use of herbal medication as an effective and safe alternative to synthesized chemical and biological treatments.
Tasly U.S. will join with 11 other Maryland-based biopharmaceutical-focused organizations as an exhibitor at BioJapan 2022, Asia’s premier partnering event for the global biotechnology industry, in Yokohama, Japan, on October 10-14. The company will discuss its aims to become a world-renowned innovator in pharmaceuticals, biologics, and nutraceuticals, and focus in particular on Dantonic® (T89), recognized as the first herbal medicine-derived compound to complete an FDA Phase III global clinical trial.